PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
Pharmaceutics · 09.04.2025 · 17 (4) · 501
DOI: 10.3390/pharmaceutics17040501 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 09.04.2025. Verfasst von Endry Wahyu Syahputra und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea government (MSIT).
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs), heterobifunctional molecules that hijack the ubiquitin–proteasome system (UPS) to degrade specific proteins, hold great promise in treating diseases driven by traditionally “undruggable” targets. However, their large molecular weight, high hydrophobicity, and other physicochemical hurdles contribute to their limited bioavailability, suboptimal pharmacokinetics, and attenuated therapeutic efficacy. Consequently, diverse formulation innovations have been investigated to optimize PROTAC delivery. This review examines current challenges and advances in specialized drug delivery approaches designed to bolster PROTAC pharmacological performance. We first outline the fundamental limitations of PROTACs—their low aqueous solubility, poor cell permeability, rapid clearance, and concentration-dependent “hook effect”. We then discuss how various enabling formulations address these issues, including polymeric micelles, emulsions, amorphous solid dispersions, lipid-based nanoparticles, liposomes, and exosomes. Collectively, these delivery technologies substantially improve the therapeutic outcomes of PROTACs in preclinical cancer models. Future applications may extend beyond oncology to address other complex diseases using newly emerging heterobifunctional molecules. By integrating advanced formulation science with innovative degrader design, the field stands poised to unlock the clinical potential of PROTACs for protein degradation therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
- College of Pharmacy, Kyungsung University, Busan 48434, Republic of Korea.
ORCID-Profile: Hyukjun Cho, Hyun Jin Park, Kwang-Su Park
Förderung
- Korea government (MSIT)
Zitieren
APA
Syahputra, E. W., Lee, H., Cho, H., Park, H. J., Park, K. S., & Hwang, D. (2025). PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation. Pharmaceutics, 17(4), 501. https://doi.org/10.3390/pharmaceutics17040501
Vancouver
Syahputra EW, Lee H, Cho H, Park HJ, Park KS, Hwang D. PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation. Pharmaceutics. 2025;17(4):501. doi:10.3390/pharmaceutics17040501
BibTeX
@article{Syahputra2025,
author = {Syahputra, Endry Wahyu and Lee, Hyunji and Cho, Hyukjun and Park, Hyun Jin and Park, Kwang-Su and Hwang, Duhyeong},
title = {PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {4},
pages = {501},
doi = {10.3390/pharmaceutics17040501}
}
EUVIMED